The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.25
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Goldman Upgrades Booker, Panmure Cuts Meggitt

Wed, 18th May 2016 08:31

LONDON (Alliance News) - The following shares received analyst recommendations Wednesday morning and Tuesday:
----------
FTSE 100
----------
JEFFERIES CUTS STANDARD CHARTERED TARGET TO 330 (400) PENCE - 'UNDERWEIGHT'
----------
GOLDMAN RAISES VODAFONE PRICE TARGET TO 265 (260) PENCE - 'NEUTRAL'
----------
BERENBERG CUTS ITV PRICE TARGET TO 230 (240) PENCE - 'HOLD'
----------
Deutsche Bank Ups Taylor Wimpey Target To 261p From 247p, Keeps Buy
----------
EXANE BNP RAISES ASHTEAD GROUP TO 'OUTPERFORM' ('NEUTRAL') - TARGET 1,050 (900) PENCE
----------
CREDIT SUISSE RAISES TRAVIS PERKINS TARGET TO 2,250 (2,200)P - 'OUTPERFORM'
----------
CREDIT SUISSE RAISES BHP BILLITON PRICE TARGET TO 1050 (900) PENCE - 'OUTPERFORM'
----------
FTSE 250
----------
PANMURE CUTS MEGGITT TO 'SELL' ('HOLD') - TARGET 325 (363) PENCE
----------
LIBERUM RAISES RIGHTMOVE PRICE TARGET TO 5,000 (4,295) PENCE - 'BUY'
----------
Numis Downgrades Marshalls To Add From Buy, Target At 400p
----------
GOLDMAN RAISES BOOKER GROUP TO 'BUY' ('NEUTRAL') - TARGET 198 (171) PENCE
----------
BERENBERG INITIATES JUST EAT WITH 'BUY' - TARGET 530 PENCE
----------
Deutsche Bank Cuts BTG Target To 740p From 755p, Keeps Buy
----------
EXANE BNP CUTS VICTREX PRICE TARGET TO 1,500 (1,650) PENCE - 'NEUTRAL'
----------
SOCGEN RAISES INTERMEDIATE CAPITAL PRICE TARGET TO 725 (660) PENCE - 'BUY'
----------
EXANE BNP CUTS ICAP TO 'NEUTRAL' ('OUTPERFORM') - TARGET 475 (550) PENCE
----------
CREDIT SUISSE CUTS SHAWBROOK PRICE TARGET TO 380 (400) PENCE - 'OUTPERFORM'
----------
MAIN MARKET AND AIM
----------
PANMURE CUTS SCANCELL HOLDINGS PRICE TARGET TO 68 (79) PENCE - 'BUY'
----------
PANMURE CUTS JOHNSTON PRESS PRICE TARGET TO 200 (230) PENCE - 'BUY'
----------
Panmure Cuts Haynes Publishing Target To 150p From 200p, Keeps Buy
----------
PANMURE RAISES HILL & SMITH PRICE TARGET TO 1,100 (950) PENCE - 'BUY'
----------
TRADERS: MERRILL LYNCH REMOVES GENEL ENERGY FROM 'EMERGING EMEA 1' LIST
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
19 Feb 2021 12:40

IN BRIEF: Scancell Non-Exec Director Diggle Sells 1.3 Million Shares

IN BRIEF: Scancell Non-Exec Director Diggle Sells 1.3 Million Shares

Read more
17 Feb 2021 16:22

IN BRIEF: Scancell Non-Exec Director Diggle Sells GBP95,000 In Shares

IN BRIEF: Scancell Non-Exec Director Diggle Sells GBP95,000 In Shares

Read more
3 Feb 2021 14:53

Scancell ends clinical development partnership with Cancer Research UK

(Sharecast News) - Novel immunotherapy developer Scancell updated the market on its SCIB2 clinical development partnership with Cancer Research UK on Wednesday, reporting that due to the impact of the Covid-19 pandemic and Cancer Research UK's re-evaluation of its collaboration model, the parties had agreed to end their clinical development partnership.

Read more
3 Feb 2021 11:20

CORRECT: AIM WINNERS & LOSERS: Brave Bison Charges Ahead

CORRECT: AIM WINNERS & LOSERS: Brave Bison Charges Ahead

Read more
3 Feb 2021 11:11

AIM WINNERS & LOSERS: Brave Bison Charges Ahead On Contract Win

AIM WINNERS & LOSERS: Brave Bison Charges Ahead On Contract Win

Read more
3 Feb 2021 09:48

Scancell Assessing SCIB2 Options As Cancer Research UK Pact Ends

Scancell Assessing SCIB2 Options As Cancer Research UK Pact Ends

Read more
29 Jan 2021 15:05

IN BRIEF: Scancell Posts Interim Pretax Loss; To Develop Virus Vaccine

IN BRIEF: Scancell Posts Interim Pretax Loss; To Develop Virus Vaccine

Read more
21 Dec 2020 19:39

Oxford Technology VCTs In Mixed Quarter Amid Scancell Rise, Ixaris Hit

Oxford Technology VCTs In Mixed Quarter Amid Scancell Rise, Ixaris Hit

Read more
18 Dec 2020 10:45

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

Read more
18 Dec 2020 10:26

Scancell Shares Rise As It Chooses Vaccine Candidate For Development

Scancell Shares Rise As It Chooses Vaccine Candidate For Development

Read more
18 Dec 2020 10:17

Scancell selects Covid-19 vaccine candidate for development and trials

(Sharecast News) - Immunotherapy developer Scancell has selected its Covid-19 vaccine candidate 'SN14' for further development and clinical trials, it announced on Friday.

Read more
16 Dec 2020 09:21

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 750,000 Shares

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 750,000 Shares

Read more
14 Dec 2020 16:59

UK DIRECTOR DEALINGS SUMMARY: Tracsis CFO Sells GBP480,000 In Shares

UK DIRECTOR DEALINGS SUMMARY: Tracsis CFO Sells GBP480,000 In Shares

Read more
25 Nov 2020 16:44

UK DIRECTOR DEALINGS SUMMARY: IG Design Chair Banks GBP1.2 Million

UK DIRECTOR DEALINGS SUMMARY: IG Design Chair Banks GBP1.2 Million

Read more
17 Nov 2020 15:40

UK EXECUTIVE CHANGE SUMMARY: Naked Wines, Tissue Regenix Make US Moves

UK EXECUTIVE CHANGE SUMMARY: Naked Wines, Tissue Regenix Make US Moves

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.